Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by dreamer05on Jan 22, 2017 9:10pm
226 Views
Post# 25739659

A few years ago..

A few years ago..When Bellus bought TLN and joined their existing ongoing project   Kiacta's already on stage 3
testing , there was a high hope this drug might suceed. However it turned out to be the opposite.
Things went down like a chute of falling water. Sp drop from 3$ to a few cents. The Shigamab
bought from TLN still in the developement phase to find another drugs for many years already.
I was a bit disappointed becasue I had high hope that may be one day we will see the light. I am still 
hoping the undergoing drug program might work that is why after so many years of absence I start
back back some shares. I hope I will run into some former shareholder of TLN, and new shareholders exchanging our views for this new company. Go luck to all shareholders who still 
have faith in this company.

Bullboard Posts